What is the recommended treatment for onychomycosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Onychomycosis

For dermatophyte onychomycosis, offer oral terbinafine 250 mg daily as first-line treatment: 6 weeks for fingernails or 12 weeks for toenails, as it demonstrates superior efficacy and lower relapse rates compared to all alternatives 1, 2.

Treatment Selection Algorithm

Systemic Therapy (First-Line)

Terbinafine is the clear winner based on the most recent 2026 British Association of Dermatologists guideline 1. The evidence is compelling:

  • Complete cure rates: 55% with terbinafine vs. 26% with itraconazole at 72 weeks 2
  • Long-term mycological cure: 46% with terbinafine vs. 13% with itraconazole at 5 years 2
  • Relapse rates: 23% with terbinafine vs. 53% with itraconazole 2
  • Minimal drug interactions compared to azoles 2

Dosing:

  • Fingernails: 250 mg daily for 6 weeks
  • Toenails: 250 mg daily for 12-16 weeks 1, 2

Alternative Systemic Options

Itraconazole - Second choice when terbinafine is contraindicated 1:

  • Continuous: 200 mg daily for 12 weeks
  • Pulse therapy: 400 mg daily for 1 week/month (2 pulses for fingernails, 3 for toenails)
  • Major caveat: Significant drug interactions, particularly with antiretrovirals 1

Fluconazole - Third-line option 1, 2:

  • 150-450 mg weekly for 3 months (fingernails) or 6+ months (toenails)
  • Less effective than terbinafine or itraconazole but better compliance with weekly dosing 2
  • Mycological cure: 47-62% for toenails, 89-100% for fingernails 2

Topical Therapy

Amorolfine 5% nail lacquer - For superficial and distal disease 1:

  • Apply once or twice weekly for 6-12 months
  • Consider for patients where systemic therapy is contraindicated 1

The 2026 guideline explicitly recommends AGAINST griseofulvin due to long treatment duration and low efficacy 1.

Special Populations

Immunosuppressed Patients

Offer terbinafine or fluconazole - avoid itraconazole due to drug interaction risks, especially with antiretrovirals 1.

Diabetes

Offer terbinafine for dermatophyte infections 1. Consider azoles only for non-dermatophyte mould or Candida infections in patients without congestive heart failure 1.

Children (1-11 years)

Weight-based dosing 1:

  • Terbinafine: 62.5 mg (<20 kg), 125 mg (20-40 kg), 250 mg (>40 kg) daily for 6 weeks (fingernails) or 12 weeks (toenails)
  • Itraconazole pulse: 5 mg/kg/day for 7 days, repeated after 21-day intervals (2 courses for fingernails, 3 for toenails)
  • Do NOT use griseofulvin despite it being the only licensed option 1

Monitoring Requirements

Baseline testing 2:

  • Liver function tests and complete blood count for patients with:
    • History of heavy alcohol consumption
    • Hepatitis
    • Haematological abnormalities
    • Children (as terbinafine is unlicensed in pediatrics)

Consider therapeutic drug monitoring for itraconazole if compliance is questionable 1.

Critical Pitfalls to Avoid

  1. Permanent taste disturbance: Rare but permanent side effect of terbinafine - warn all patients 2

  2. Dermatophytoma: Dense white lesions under the nail are resistant to antifungals alone - requires physical removal first 2

  3. Recurrence prevention 1:

    • Replace or sanitize contaminated footwear
    • Apply topical antifungal shoe sprays weekly or twice monthly
    • Treat concomitant tinea pedis
    • Screen family members
  4. Re-evaluate at 3-6 months after treatment initiation - give further treatment if disease persists 2

  5. Hepatotoxicity risk: Though minimal with terbinafine, serious hepatic toxicity has occurred in patients with pre-existing liver disease - avoid in active/chronic liver disease 2

When Combination Therapy Makes Sense

The 2026 guideline suggests considering combination topical + systemic therapy when response to monotherapy is likely poor 1, though specific criteria aren't detailed. This typically applies to severe disease with >60% nail involvement or matrix involvement.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.